Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AAHI-SC2 Vaccine
- Development stage
- Unknown
- Lead developer
- Access to Advanced Health Institute
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
AAHI-SC2 is a self-amplifying RNA (saRNA) vaccine candidate designed to prevent COVID-19 by targeting the SARS-CoV-2 spike (S) protein. Developed by the Access to Advanced Health Institute (AAHI) in collaboration with ImmunityBio and AccessBio, the vaccine utilizes a nanostructured lipid carrier (NLC) delivery system that incorporates an adjuvant, making it both self-amplifying and self-adjuvanted. A significant advantage of AAHI-SC2 is its thermostability; it can be lyophilized for storage at standard refrigerated temperatures for at least 10 months or at room temperature for up to six months, facilitating distribution in resource-limited settings. It is currently being evaluated as a booster in the Phase 1/2 THEMBA II clinical trial (NCT05370040) in South Africa.
- Other names
- AAHI-SC2 COVID-19 VaccineAAHI-SC-2 COVID-19 VaccineAAHI-SC 2 COVID-19 Vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on AAHI-SC2 Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AAHI-SC2 Vaccine.